Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Itacitinib in bronchiolitis obliterans syndrome after lung transplant
NCT03978637Phase 2Terminated
- Sponsor
- Incyte
- Start
- Feb 2020
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of itacitinib in Bronchiolitis Obliterans Syndrome (BOS), sponsored by Incyte. Started Feb 2020; status: terminated.
02
Drugs
itacitinib
03
Conditions
Bronchiolitis Obliterans Syndrome (BOS)
Beyond the preview
Go deeper on NCT03978637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03978637.